Back

Withdrawal of GDMT in patients with a recovered LV and reversible etiology: a scenario in valvular regurgitation

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Challenges and strategies in heart failure care Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Yu Kang

West China Hospital, Sichuan University, Chengdu (China)

5 More presentations in this session

Presentation thumbnail
Physical exercise or cognitive behavioural therapy for takotsubo cardiomyopathy: a randomised controlled trial
Doctor D. Gamble (Aberdeen, GB)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of natriuresis-guided diuresis in acute decompensated heart failure: a meta-analysis
Doctor T. Fretz (Indianapolis, US)
Abstract Slides Video
Presentation thumbnail
Therapeutic implementation in patients with newly diagnosed heart failure: data from the italian multicenter registry OpTIMa-HF
Doctor F. Marzano (Naples, IT)
Abstract Slides Video
Presentation thumbnail
TELESAT-HF study: persistent reduction of all-cause mortality across age categories in a real-world heart failure population
Professor N. Girerd (Nancy, FR)
Abstract Slides Video
Presentation thumbnail
Remote monitoring program in patients with pulmonary hypertension: the French experience
Doctor C. Fauvel (Rouen, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Challenges and strategies in heart failure care

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
The power of optimal medical therapy in heart failure with secondary mitral regurgitation
thumbnail
Congress Presentation
Effect of improving utilization of guideline-directed medical therapy for heart failure.
thumbnail
Congress Presentation
Relationship between left ventricular reverse remodeling and guideline-directed medical therapy intensity in de novo heart failure with reduced ejection fraction patients: insight from TRANS-HF trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources